See more : Avation PLC (AVAP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Senseonics Holdings, Inc. (SENS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senseonics Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- ACE ENGITECH LIMITED (ACEENGITEC.BO) Income Statement Analysis – Financial Results
- Sunway International Holdings Limited (0058.HK) Income Statement Analysis – Financial Results
- AviChina Industry & Technology Company Limited (2357.HK) Income Statement Analysis – Financial Results
- Total Access Communication Public Company Limited (DTAC.BK) Income Statement Analysis – Financial Results
- Alturas Minerals Corp. (ALTSF) Income Statement Analysis – Financial Results
Senseonics Holdings, Inc. (SENS)
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.39M | 16.39M | 13.68M | 4.95M | 21.30M | 18.91M | 6.37M | 332.00K | 38.00K | 0.00 | 17.00K |
| Cost of Revenue | 19.30M | 13.66M | 14.49M | 22.32M | 40.75M | 27.06M | 9.76M | 660.00K | 118.00K | 0.00 | 5.00K |
| Gross Profit | 3.09M | 2.73M | -811.00K | -17.37M | -19.45M | -8.15M | -3.39M | -328.00K | -80.00K | 0.00 | 12.00K |
| Gross Profit Ratio | 13.81% | 16.63% | -5.93% | -350.90% | -91.30% | -43.07% | -53.11% | -98.80% | -210.53% | 0.00% | 70.59% |
| Research & Development | 48.75M | 39.72M | 27.22M | 20.41M | 38.43M | 31.86M | 30.74M | 26.35M | 18.25M | 12.88M | 13.79M |
| General & Administrative | 0.00 | 0.00 | 21.54M | 20.80M | 23.23M | 19.84M | 15.34M | 13.02M | 9.81M | 5.73M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 7.62M | 20.55M | 49.56M | 27.73M | 6.86M | 2.74M | 792.00K | 95.00K | 0.00 |
| SG&A | 29.94M | 31.63M | 29.15M | 41.35M | 72.78M | 47.57M | 22.19M | 15.76M | 10.60M | 5.82M | 5.01M |
| Other Expenses | 0.00 | -102.00K | -174.00K | -311.00K | -511.00K | -321.00K | 176.00K | 25.00K | 26.00K | 0.00 | 0.00 |
| Operating Expenses | 78.69M | 71.35M | 56.37M | 61.76M | 111.21M | 79.43M | 52.93M | 42.11M | 28.85M | 18.70M | 18.80M |
| Cost & Expenses | 97.99M | 85.02M | 70.86M | 84.08M | 151.96M | 106.49M | 62.69M | 42.77M | 28.85M | 18.70M | 18.81M |
| Interest Income | 5.36M | 1.82M | 243.00K | 175.00K | 1.93M | 2.00M | 135.00K | 80.00K | 9.00K | 0.00 | 10.00K |
| Interest Expense | 11.11M | 18.70M | 16.72M | 16.17M | 12.20M | 8.28M | 3.10M | 1.60M | 1.10M | 191.00K | 0.00 |
| Depreciation & Amortization | 1.28M | 985.00K | 1.24M | 1.14M | 1.00M | 270.00K | 227.27K | 155.00K | 118.00K | 189.00K | 220.00K |
| EBITDA | -48.01M | 161.81M | -284.52M | -157.86M | -99.41M | -85.42M | -55.77M | -42.17M | -28.66M | -18.51M | -18.57M |
| EBITDA Ratio | -214.40% | -408.23% | -417.65% | -1,859.91% | -622.43% | -454.17% | -875.18% | -12,702.71% | -75,418.42% | 0.00% | -109,229.41% |
| Operating Income | -75.60M | -68.63M | -57.18M | -79.13M | -130.66M | -87.58M | -56.31M | -42.43M | -28.81M | -18.70M | -18.79M |
| Operating Income Ratio | -337.66% | -418.74% | -418.15% | -1,598.91% | -613.41% | -463.06% | -883.62% | -12,781.02% | -75,821.05% | 0.00% | -110,523.53% |
| Total Other Income/Expenses | 15.21M | 210.75M | -245.29M | -96.04M | 15.11M | -6.39M | -2.79M | -1.50M | -1.07M | -183.00K | 10.00K |
| Income Before Tax | -60.39M | 142.12M | -302.48M | -175.17M | -115.55M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Income Before Tax Ratio | -269.73% | 867.16% | -2,211.88% | -3,539.46% | -542.46% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| Income Tax Expense | 0.00 | 18.70M | 15.31M | 15.86M | 10.69M | 6.39M | 2.79M | 1.50M | 1.07M | 183.00K | 0.00 |
| Net Income | -60.39M | 142.12M | -317.78M | -191.02M | -126.23M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Net Income Ratio | -269.73% | 867.16% | -2,323.81% | -3,859.85% | -592.62% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| EPS | -0.11 | 0.30 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| EPS Diluted | -0.11 | -0.11 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| Weighted Avg Shares Out | 567.97M | 467.95M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
| Weighted Avg Shares Out (Dil) | 567.97M | 618.21M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
Eversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Eversense® CGM System Receives iCGM Designation by the US FDA.
Eversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes...
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* PARSIPPANY, N.J. , March 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes...
Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense® Post Approval Study is...
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare...
Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.01 per share a year ago.
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year...
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter...
MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM
The decision is further recognition of Eversense as an important option for people with diabetes PARSIPPANY, N.J. , Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company...
Source: https://incomestatements.info
Category: Stock Reports